News

The technology was developed by Michael Czech, professor and chair, program in molecular medicine at the University of Massachusetts Medical School (UMMS) and an RXi founder, and Gary

The product utilizes the company’s proprietary Strattice technology, which is a sterile reconstructive tissue matrix that supports tissue regeneration. The Strattice technology is a porcine-based, acellular dermal matrix

The company believes the positive opinion of the Committee for Orphan Medicinal Products (COMP) will serve as the scientific basis for the European Commission to issue a EU

According to the company, preclinical studies demonstrated that INS-20 and the FDA-approved Neulasta are comparable in both their pharmacological and toxicological profile. Detailed analytical characterization also demonstrated that

In this newly created position, Dr Geehr will be responsible for the commercial, manufacturing and marketing operations of Abraxis. Most recently, Dr Geehr has been serving as president

With this approval, the company expects to begin enrolling patients into its Prospect II study this quarter, with preliminary results anticipated during the second half of 2009. The

The studies were conducted with a formulation based on HemCon’s newest proprietary platform technology that provides a controlled release broad spectrum antifungal and antibacterial agent to fight infection.

Upon issuance, the patent will broadly cover methods of treating obesity with combinations of bupropion and naltrexone, the two active agents in Contrave. It is a companion to

The three inventions Neuralstem has licensed from Cleveland Clinic are: a stabilized platform and microelectrode recording guidance validation, a floating cannula for spinal cord therapeutic injection, and a